AUG 11, 2026 · PHASE 1 TRIAL
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
ClinicalTrials.gov
This is a first-in-human Phase 1 dose-escalation study with safety and pharmacokinetic endpoints; no results are posted in this registry record, so the evidence base is not yet available for assessment.
Reported
Planned enrollment45
Study phasePHASE 1
Primary outcome: treatment-emerge…Up to 90 days after last administration